-
[show abstract]
[hide abstract]
ABSTRACT: In the present study, we aimed to investigate the tumor-inhibiting effects of recombinant human endostatin (rhES) combined with paclitaxel-cisplatin (TP regimen) on human breast cancer in xenograft-bearing nude mice. A total of 24 mice bearing human breast cancer xenografts were administered both rhES and TP, TP alone, rhES alone or saline. The tumor growth inhibition was observed. Serum vascular endothelial growth factor (VEGF) levels and microvessel density (MVD) were determined by ELISA and immunohistochemistry, respectively. Cell apoptosis was detected using terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) staining. Survival time was observed in another 24 nude mice with the same treatment. MVD expression in the group administered rhES and TP was lower than that in the other groups (P<0.05); serum VEGF levels in the combined drug group were lower compared to the other groups; the apoptotic index increased in the combined drug group. We conclude that the effect of the TP regimen combined with rhES on breast cancer is better than that of the TP regimen alone.
Experimental and therapeutic medicine 02/2012; 3(2):159-164.
-
[show abstract]
[hide abstract]
ABSTRACT: IL-17, which exerts strong pro-inflammatory effects, has emerged as an important mediator in inflammation-associated cancer. However, the characteristics of IL-17-producing cells, the relevance of IL-17 to clinical parameters and its function in the development and progression of colorectal carcinoma still remain to be explored. In the present study, we first found the levels of IL-17 producing cells were significantly increased in the tumor regions of samples from colorectal carcinoma patients compared with non-tumor regions. Confocal microscopic analysis showed co-staining of IL-17 with CD4 and CD68, indicating IL-17 in colorectal carcinoma was expressed by macrophage and Th17. High expression of IL-17 was associated with high microvessel density. Univariate and multivariate analysis revealed that IL-17 was an independent prognostic factor for overall survival. To explore the underlying mechanisms of IL-17 in angiogenesis, we used PCR-array to find pro-angiogenic factor in cancer cells specifically induced by IL-17, then validated VEGF as one of factors in IL-17-mediated angiogenesis with the use of quantitative RT-PCR, ELISA and VEGF immunohistochemistry. Our results propose IL-17 as a novel indicator of prognosis in the patients with colorectal carcinoma and could serve as a novel therapeutic target for colorectal carcinoma, furthermore our results indicate that IL-17 producing cells may facilitate development of colorectal carcinoma by fostering angiogenesis via promote VEGF production from cancer cells.
Biochemical and Biophysical Research Communications 03/2011; 407(2):348-54. · 2.48 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Dendritic cells (DC), the most potent antigen presenting cells (APC), have been shown able to process apoptotic tumor cells and necrotic tumor cells for antigen presentation. Apoptosis and necrosis are the two common final pathways through which the tumors are killed by chemotherapy or radiation therapy. The tumor cells receiving radiation often produce the "danger signal" cytokines such as TNF-alpha and IL-1. Another cytokine MIP-3alpha that is able to attract DC to the tumor site is normally not secreted. We hypothesize that if artificial introduction of a large number of DC to the necrotic tumor site after radiation therapy by transfecting any cells at the tumor site to secrete DC-tropic MIP-3alpha, an anti-tumor immune response would be initiated. C57BL/6J mice bearing a well-known Lewis lung carcinoma are used to assess efficacy of this modality. The plasmid DNA containing pcDNA3.1/MIP-3alpha was injected into the subcutaneous tumors after radiation treatment. We demonstrate a detectable local expression of MIP-3alpha and local accumulation of DC. Tumor infiltrating lymphocytes after the treatment are predominantly CD8+ T-cells with rare CD4+ T-cells. The anti-tumor immune response was also measurable, which contributes at least in part to the finding that the treated mice have smaller tumor and prolonged survival, comparing to the control groups. This study suggests a potential new means of immune modulation and provides us a new concept of immunotherapy of cancer.
Immunology Letters 04/2006; 103(2):101-7. · 2.53 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Dendritic cells (DC), the most potent antigen presenting cells (APC), have been shown able to process apoptotic tumor cells and necrotic tumor cells for antigen presentation. Apoptosis and necrosis are the two common final pathways through which the tumors are killed by chemotherapy or radiation therapy. The tumor cells receiving radiation often produce the “danger signal” cytokines such as TNF-α and IL-1. Another cytokine MIP-3α that is able to attract DC to the tumor site is normally not secreted. We hypothesize that if artificial introduction of a large number of DC to the necrotic tumor site after radiation therapy by transfecting any cells at the tumor site to secrete DC-tropic MIP-3α, an anti-tumor immune response would be initiated. C57BL/6J mice bearing a well-known Lewis lung carcinoma are used to assess efficacy of this modality. The plasmid DNA containing pcDNA3.1/MIP-3α was injected into the subcutaneous tumors after radiation treatment. We demonstrate a detectable local expression of MIP-3α and local accumulation of DC. Tumor infiltrating lymphocytes after the treatment are predominantly CD8+ T-cells with rare CD4+ T-cells. The anti-tumor immune response was also measurable, which contributes at least in part to the finding that the treated mice have smaller tumor and prolonged survival, comparing to the control groups. This study suggests a potential new means of immune modulation and provides us a new concept of immunotherapy of cancer.
Immunology Letters - IMMUNOL LETT. 01/2006; 103(2):101-107.
-
[show abstract]
[hide abstract]
ABSTRACT: To improve the efficacy and selectivity of gene therapy for lung cancer through inducing oncostatin M (OSM) gene expression by radiation via the early growth response gene-1 (Egr-1) promoter.
The radio-inducible OSM gene was constructed by insertion of Egr-1 promoter into upstream of the OSM gene. The expression of OSM in lung adenocarcinoma cell line A549 which was transfected with pEO and exposed to different doses of γ-ray irradiation was analyzed, and the relative survival fraction of cells and cell survival curve were observed. To examine the efficacy of this pEO gene therapy in vivo, the tumor supression effects were investigated in 40 nude mice bearing lung tumors.
Expression of OSM gene in A549 cells transfected with pEO plasmids was markedly upregulated in a radiation dose-dependent manner. A gene therapy experiment in vitro showed that pEO transfected A549 cells became highly sensitive to ionizing radiation. pEO transfected tumors regressed significantly after a combination therapy with irradiation in all mice (n=10), and three tumors disappeared in 3 weeks without any side effect.
The results indicate that tumor targeted expression of OSM gene under the control of a radio-inducible promoter represents a novel strategy for safe and effective gene therapy for lung cancer and might be widely applied in the future.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 12/2004; 7(6):467-70.
